VAZALORE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vazalore, and what generic alternatives are available?
Vazalore is a drug marketed by Plx Pharma and is included in one NDA. There are four patents protecting this drug.
This drug has twenty patent family members in nine countries.
The generic ingredient in VAZALORE is aspirin. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aspirin profile page.
DrugPatentWatch® Generic Entry Outlook for Vazalore
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 29, 2032. This may change due to patent challenges or generic licensing.
There is one tentative approval for the generic drug (aspirin), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VAZALORE?
- What are the global sales for VAZALORE?
- What is Average Wholesale Price for VAZALORE?
Summary for VAZALORE
| International Patents: | 20 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Patent Applications: | 3,952 |
| What excipients (inactive ingredients) are in VAZALORE? | VAZALORE excipients list |
| DailyMed Link: | VAZALORE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VAZALORE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VAZALORE
| Drug Class | Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor |
| Mechanism of Action | Cyclooxygenase Inhibitors |
| Physiological Effect | Decreased Platelet Aggregation Decreased Prostaglandin Production |
US Patents and Regulatory Information for VAZALORE
VAZALORE is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VAZALORE is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VAZALORE
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TEMPORARY REDUCTION OF FEVER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-002 | Feb 26, 2021 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-002 | Feb 26, 2021 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VAZALORE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VAZALORE
When does loss-of-exclusivity occur for VAZALORE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 12315545
Patent: pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 50187
Patent: VECTEURS DEPENDANT DU PH POUR LIBERATION CIBLEE DE PRODUITS PHARMACEUTIQUES DANS LE TUBE DIGESTIF, COMPOSITIONS PREPAREES A PARTIR DE CEUX-CI, ET LEUR FABRICATION ET LEUR UTILISATION (PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
China
Patent: 3957888
Patent: Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 60433
Patent: VECTEURS DÉPENDANT DU PH POUR LIBÉRATION CIBLÉE DE PRODUITS PHARMACEUTIQUES DANS LE TUBE DIGESTIF, COMPOSITIONS PRÉPARÉES À PARTIR DE CEUX-CI, ET LEUR FABRICATION ET LEUR UTILISATION (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 00098
Patent: 用於將藥物沿胃腸道靶向釋放的 依賴性載體、其組合物及其製備和應用 (PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME PH)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 68645
Estimated Expiration: ⤷ Sign Up
Patent: 99504
Estimated Expiration: ⤷ Sign Up
Patent: 14531460
Patent: 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用
Estimated Expiration: ⤷ Sign Up
Patent: 17222650
Patent: 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用 (PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 20090499
Patent: 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用 (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 0951
Patent: PORTADORES DEPENDIENTES DEL PH PARA LA LIBERACION DIRIGIDA DE PRODUCTOS FARMACEUTICOS A LO LARGO DEL TRACTO GASTROINTESTINAL, COMPOSICIONES DE LOS MISMOS, Y FABRICACIÓN Y USO DE LAS MISMAS. (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME.)
Estimated Expiration: ⤷ Sign Up
Patent: 6017
Patent: PORTADORES DEPENDIENTES DE PH PARA LA LIBERACION DIRIGIDA DE PRODUCTOS FARMACEUTICOS A LO LARGO DEL TRACTO GASTROINTESTINAL, COMPOSICIONES DE LOS MISMOS, Y FABRICACION Y USO DE LAS MISMAS. (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME.)
Estimated Expiration: ⤷ Sign Up
Patent: 14003890
Patent: PORTADORES DEPENDIENTES DEL PH PARA LA LIBERACION DIRIGIDA DE PRODUCTOS FARMACEUTICOS A LO LARGO DEL TRACTO GASTROINTESTINAL, COMPOSICIONES DE LOS MISMOS, Y FABRICACIÓN Y USO DE LAS MISMAS. (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME.)
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2162901
Estimated Expiration: ⤷ Sign Up
Patent: 2180667
Estimated Expiration: ⤷ Sign Up
Patent: 2188840
Estimated Expiration: ⤷ Sign Up
Patent: 140105436
Patent: PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 200008032
Patent: 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 (pH PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT COMPOSITIONS THEREFROM AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 200118219
Patent: 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 (pH PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT COMPOSITIONS THEREFROM AND MAKING AND USING SAME)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VAZALORE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1200098 | 用於將藥物沿胃腸道靶向釋放的 依賴性載體、其組合物及其製備和應用 (PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME PH) | ⤷ Sign Up |
| Portugal | 1343529 | ⤷ Sign Up | |
| Australia | 2001297778 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 02085414 | ⤷ Sign Up | |
| Cyprus | 1110474 | ⤷ Sign Up | |
| South Korea | 20140105436 | PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VAZALORE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0984957 | 122012000017 | Germany | ⤷ Sign Up | PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812 |
| 0984957 | 2012/048 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
